Traynor Capital Management Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,803 shares of the company’s stock after acquiring an additional 1,048 shares during the period. Traynor Capital Management Inc.’s holdings in Johnson & Johnson were worth $2,432,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of JNJ. Virtus ETF Advisers LLC bought a new position in shares of Johnson & Johnson in the second quarter worth $25,000. Krane Funds Advisors LLC bought a new position in shares of Johnson & Johnson in the second quarter worth $26,000. Financial Advantage Inc. bought a new position in shares of Johnson & Johnson in the third quarter worth $28,000. Crewe Advisors LLC grew its stake in shares of Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares in the last quarter. Finally, Eii Capital Management Inc. bought a new position in shares of Johnson & Johnson in the third quarter worth $39,000. 72.25% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on JNJ shares. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Friday, October 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Wells Fargo & Co decreased their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price target for the company in a research note on Thursday, October 17th. Finally, Goldman Sachs Group set a $169.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $151.64.
JNJ stock traded down $1.02 during trading hours on Monday, hitting $131.98. 4,368,140 shares of the stock traded hands, compared to its average volume of 7,211,292. The stock has a 50-day simple moving average of $130.83 and a 200 day simple moving average of $134.05. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99. The company has a market cap of $343.25 billion, a P/E ratio of 16.13, a P/E/G ratio of 2.20 and a beta of 0.69. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The business had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter last year, the business posted $2.05 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 8.65 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.88%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is a Lock-Up Period?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.